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Abstract The pteridine compounds neopterin and 7,8-dihy- 
droneopterin serve as valuable indicators for the stimulation of 
the cellular immune system. Whether they exhibit distinct bio- 
chemical functions in the immunological process is at present 
under discussion. We show that neopterin, but not 7,8-dihydrone- 
opterin, is a stimulus for iNOS gene expression in rat vascular 
smooth muscle cells in vitro. At a concentration of 20/zM, neop- 
terin leads to an iNOS mRNA expression of 2.5 amol iNOS 
cDNM~g total RNA. When cells were coincubated with 20 pM 
neopterin and 5 pg/ml lipopolysaccharide derived from Escheric- 
hia coli, at least an additive effect on iNOS mRNA expression 
could be detected (iNOS cDNA concentration was 5.0 amol/pg 
total RNA). We speculate that neopterin enhances the macro- 
phage-induced extracellular toxicity. This might be of relevance 
in situations associated with excessive release of cytokines, neop- 
terin, and nitric oxide, as observed in septic shock. 
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1. Introduction 
Neopterin and 7,8-dihydroneopterin are heterocyclic pterid- 
ine compounds which are synthesized and released in excess by 
monocytes/macrophages upon stimulation with interferon-?' 
[1]. Therefore, neopterin has become a valuable diagnostic 
marker in a number of conditions associated with increased 
activity of the cellular immune system, e.g. AIDS or hepatits 
[2]. In spite of this, it remains elusive whether pteridines per se 
exhibit any biochemical functions. Recent data suggest that 
neopterin and 7,8-dihydroneopterin may interfere with the cy- 
totoxic mechanisms of activated macrophages since neopterin 
was found to potentiate the effects of reactive oxygen species 
whereas lower doses of 7,8-dihydroneopterin appeared to be an 
oxygen radical scavenger [3,4]. On the other hand, a high con- 
centration of  7,8-dihydroneopterin in combination with tumor 
necrosis factor-~ (TNF-~) was demonstrated to enhance apop- 
tosis due to oxidative stress [5]. In addition, Barak and Gruener 
[6] described an augmentation of TNF-c~-production i  periph- 
eral blood mononuclear cells and macrophages following si- 
multaneous timulation with neopterin and either lipopolysac- 
charide (LPS) from Escherichia coli or interferon-?' (1FN-T). 
Therefore, one may speculate that pteridines play a role as 
modulators in situations associated with Gram-negative n- 
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dotoxemia nd with increased activity of several inflammatory 
cytokines. 
It is well known that bacterial endotoxins as well as cytokines 
like TN F-~ and IFN-?' are potent stimulators of inducible nitric 
oxide synthase (iNOS) gene expression in various cell types, e.g. 
vascular smooth muscle cells (VSMC). iNOS stimulation leads 
to an excessive formation of the vasodilating compound nitric 
oxide [7-9] which is assumed to be the final pathway of the 
pathophysiological hypotensive reaction characteristic of septic 
shock. Since neopterin levels were found to be increased in 
patients with sepsis [10], the present experiments were carried 
out to investigate whether neopterin and 7,8-dihydroneopterin 
interfere with iNOS gene expression in vitro. 
2. Materials and methods 
2. I. Reagents 
Dulbecco's modified Eagle's medium (DMEM) with phenol red was 
purchased from ccPro, Karlsruhe, Germany. DMEM without phenol 
red, L-arginine, collagenase I, trypsin inhibitor, N-(l-naphthylethyl- 
ene)diamine, fl-NADPH, lipopolysacharide (LPS) derived from E. coli 
t serotype 01l 1 :B4), and the phenol-chloroform-isoamyl alcohol mix- 
ture were from Sigma Chemicals, Deisenhofen, Germany. Fetal calf 
serum tFCS), penicillin-streptomycin, trypsin-EDTA, and M-MLRV 
superscript reverse transcriptase were purchased from Gibco Life 
Tech., Eggenstein, Germany. Elastase and sulfanilamide were fiom 
Serva, Heidelberg, Germany. Oligo(dT) 15 and dNTP-mix were from 
Amersham Buchler, Braunschweig, Germany. Taq polymerase and 
primer sets were obtained from Biometra, G6ttingen, Germany; guani- 
dine isothiocyanate was from Roth, Karlsruhe, Germany; and nitrate 
reductase was from Boehringer, Mannheim, Germany. Recombinant 
rat interferon-}, (IFN-T) was from IC Chemicals, Ismaning, Germany; 
neopterin and 7,8-dihydroneopterin were purchased from Schircks 
Lab., Jona, Switzerland. 
Possible cytotoxicity of the pteridines was assessed by means of the 
[3-(4,5-dimethylthiazol-2-yl)-2,5-piphenyl]tetrazolin bromide assay. No 
cytotoxicity was observed. 
2.2. Preparation of rat aortic vascular smooth muscle cells' 
VSMC from WKY rats were isolated using a modified method orig- 
inally described by Chamley et al. [11]. The rats were decapitated under 
ether anesthesia and the thoracic aorta was dissected out immediately. 
The surrounding adipose and connective tissue was removed and the 
aorta was incubated at 37°C for 30 min in DMEM containing collage- 
nase I 1385 U/ml), elastase (90 U/ml), trypsin inhibitor (inhibiting ca- 
pacity 0.85 mg trypsin/ml), streptomycin (50/lg/ml), penicillin (50 U/ 
ml), and 10% FCS in a humidified atmosphere of 95% air/5% CO2. 
Afterwards, the adventitia was stripped off, the aorta was minced with 
scalpels and again incubated at 37°C for 2 h under continuous stirring 
in DMEM containing the supplements mentioned above. The resulting 
VSMC suspension was centrifuged for 5 min at 400 x g. 
The pellet was resuspended in fresh DMEM and the cells were plated 
on 35 × 10 mm culture dishes and grown at 37°C in a humidified 
atmosphere of95% air/5% CO,. After 5--7 days, confluent cultures were 
passaged by incubation (10 rain at 37°C) in phosphate-buffered saline 
solution (PBS: 137 mM NaCI, 2.7 mM KC1, 8.1 mM Na2HPO4, 1.5 mM 
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KH2PO ~, pH 7.4t containing (I.05% trypsin and 0.02% EDIA. Subcul- 
tured cells were grown in 75 cm-" culture flasks (Falcon). For experi- 
ments, passages 4-12 were used. A total of five different cell prepara- 
tions from WKY was used in the present study. 
2.3. Nitrite and nitrate assay 
Synthesis of the stable NO metabolites nitrite and nitrate was deter- 
mined in the cell-free supernatant cultures incubated for 48 h in L- 
arginine nriched medium without phenol red. Nitrate was reduced to 
nitrite by nitrate reductase (0.4 U/ml), in the presence of 10 mM fl- 
NADPH. Total nitrite accumulation was assayed by the Greiss reaction 
[121. 
2.4. RNA isolation and polymerase chain reaction 
At the end of the 9 h experiments cells were washed with phosphate- 
buffered saline and lysed with 4 M guanidinium isothiocyanate contain- 
ing 0.1 M 2-mercaptoethanol. T tal RNA was isolated by acid phenol- 
chloroform extraction according to the method by Chomczynski and 
Sacchi [13], redissolved in water and determined photometrically at a 
wavelength of260 nm. 1/zg total RNA was reverse-transcribed into first 
strand cDNA using oligo(dT)15 as a primer for reverse transcriptase. 
RT-generated cDNA encoding for rat inducible NOS and rat glyceral- 
dehyde-3-phosphate dehydrogenase (GAPDH) genes were amplified 
using PCR. Expression of the housekeeping gene GAPDH served as 
control: RNA with no GAPDH band was excluded from further inves- 
tigations. PCR was pertbrmed inPCR buffer (50 mM Tris-HCl, pH 8.3, 
50 mM KC1, 1.5 mM MgCI> 0.001% w/v gelatine), 0.2 mM of each 
dNTP, 300 nM of each 5' and 3' primer and 2 U/ml ofTaq polymerase 
in a 50/al reaction volume. PCR was run for 30 cycles after an initial 
denaturation step at 94°C for 3 min with an amplification profile of 
each cycle consisting of denaturation for 1 rain at 94°C, primer anneal- 
ing for 1.5 min at 58°C and elongation for 3 min at 73°C. 
For quantitative analysis of iNOS cDNA, a competitive PCR was 
performed using a neutral non-homologous DNA fragment derived 
from the viral oncogene V-erb B to which the iNOS primer template 
sequences had been added (Competitive DNA MIMIC. Clontech, as 
described by Siebert and Larrick [14]). The use of this internal standard 
allows one to determine the absolute amount of target iNOS cDNA. 
Known molecular quantities of the standard cDNA were spiked into 
a series of PCR reaction tubes containing equal amounts of the iNOS 
cDNA. The PCR setup was as described above, with one exception: for 
competitive analyses, only 25 cycled PCR were performed. 
Following PCR, the amount of products generated by the internal 
standard as well as by the iNOS target were compared. The initial 
amounts of iNOS eDNA and competititor eDNA were assumed to be 
equal in those reactions where the molar ratio of iNOS and standard 
products was jugded to be equal. 
Oligonucleotide primers for iNOS and internal standard were: 5' 
CCCTTCCGAAGTTTCTGGCAGCAGG 3' (upstream), and 5' GG- 
CTGTCAGAGCCTTGTGCCTTTGG 3' (downstream) correspond- 
ing to the murine macrophage iNOS [15]. Oligonucleotide primers tbr 
GAPDH were: 5' GCAGGGGGAGCCAAAAGGG 3' (upstream) and 
5' TGCCAGCCCCAGCGTCAAAG 3'(downstream) corresponding 
to the human GAPDH gene [16]. 
2.5. Statistical anah'si.~ 
Results are expressed as mean values + standard error of the mean 
(SEM). To test for significance of differences between the mean value 
of a control vs. the mean value of treated cells. Tukey's t-test was used. 
P values <0.05 were considered to be significant. 
3. Results 
Fig. 1 summarizes the results of the qualitative analysis of 
iNOS mRNA expression measured as iNOS cDNA following 
the different 9 h incubation protocols. IFN-y (100 U/ml), LPS 
(5 /~g/ml), neopterin (20/~M) as well as the combinat ion of 
neopter in/ IFN-y,  7,8-dihydroneopterin (20 ¢tM)/1FN-y, neop- 
terin/LPS, and 7,8-dihydroneopterin/LPS increased iNOS 
mRNA expression. In contrast, no iNOS cDNA could be de- 
tected in unstimulated cells {C) and in cells treated with 7.8- 
dihydroneopterin alone. Fig. 2 shows the results o fa  compara- 
Fig. 1. Qualitative analysis of iNOS mRNA expression detected as 
iNOS eDNA (length: 498 base pairs) following 9 h incubations of 
vascular smooth muscle cells with: 100 U/ml interferon-y (IFN-y), 5 
/ag/ml lipopolysaccharide (LPS), 20/aM neopterin (N20) 20 pM 7,8- 
dihydroneopterin (NH20), 20/aM neopterin + 100 U/ml interferon-)' 
(N20 + IFN-y), 20/aM 7,8-dihydroneopterin + 100 U/ml interferon-)' 
(NH20 + IFN-y), 20 /aM neopterin + 5 /ag/ml lipopolysaccharide 
(N20 + LPS), and 20/aM 7,8-dihydroneopterin + 5/ag/ml lipopolysac- 
charide (NH20 + LPS), respectively. Lane C shows the control experi- 
ments in unstimulated cells, lane M indicates the molecular marker. The 
lower part of the figure shows the corresponding GAPDH bands 
(length: 567 base pairs). Expressionof the housekeeping GAPDH gene 
served as internal control. Results are representative of three different 
experiments. 
tive quantif ication of iNOS cDNA following 9 h incubations 
with neopterin, LPS, and coincubation of cells with neopterin 
and LPS, respectively. Neopterin enhanced iNOS mRNA ex- 
pression (2.5 amol/pg cDNA),  while LPS treatment resulted in 
an iNOS cDNA concentrat ion of 1.0 amol/ctg total RNA.  
When VSMC were coincubated with neopterin and LPS, at 
least an additive effect on iNOS mRNA expression (iNOS 
cDNA concentrat ion was 5.0 amol//zg total RNA)  could be 
found. Further results of iNOS cDNA quantif ication analyses 
are given in Fig. 3. No difference in iNOS gene expression could 
be detected when cells were coincubated with 7,8-dihydroneop- 
terin and LPS as compared to cells treated with LPS alone. In 
both experiments iNOS cDNA concentrat ion was 1 amol/pg 
total RNA. IFN-7/ strongly enhanced iNOS mRNA produc- 
tion. During 9 h incubation the iNOS cDNA concentrat ion 
increased to 50 amol//tg total RNA.  This effect was not influ- 
enced by coincubation of cells with either neopterin/IFN-?" or 
7,8-dihydroneopterin/ IFN-y, both resulting in identical iNOS 
eDNA levels of 50 amol/ctg total RNA.  
Table 1 summarizes the results of the nitrite/nitrate determi- 
nat ion in cell-free culture supernatants following 24 and 48 h 
incubation. Stimulation of iNOS at the mRNA level (Fig. 1) 
was accompanied by an accumulation of nitrite/nitrate in the 
supernatants, thus indicating that the VSMC were activated to 
produce nitric oxide. Neopter in enhanced the formation of 
nitrite compared to controls and was also effective in LPS- 
treated cultures. In contrast, 7,8-dihydroneopterin decreased 
nitrite formation in the cell cultures stimulated with IFN-y  or 
LPS. The absolute amount  of nitrite produced was greater in 
cultures incubated for 48 h compared to 24 h. However, the 
I ' ,  
influence of incubations with IFN-y, LPS and neopterin deriv- 
atives showed the same characteristics (Table 1). 
Using higher concentrations of neopterin derivatives, e.g. 
200 ¢tM, also only marginally affected the results: after 24 h 
nitrite production was 6.38 + 0.31 nmol nitrite/106 cells when 
neopterin was added, being 2.40 + 0.12 nrnol/106 cells in the 
case of 7,8-dihydroneopterin. Coincubation of 200 tiM neop- 
terin with IFN-g (25.73 + 0.35 nmol nitrite/106 cells) or LPS 
(12.75 + 0.30) induced slightly higher nitrite concentrations 
compared to 20 pM neopterin (Table 1). 200 /~M 7,8-dihy- 
droneopterin decreased nitrite production to an extent similar 
to that with 20 ¢tM 7,8-dihydroneopterin (4.45 _+ 0.34; Table 
1) but the nitrite production induced by IFN-), was more de- 
creased with the 200/IM dose (15.81 + 0.35) compared to the 
20 ~tM dose (Table 1). 
4. D iscuss ion  
Our data demonstrate hat neopterin stimulates iNOS gene 
expression at the mRNA level with a concomitant increase in 
nitric oxide production. The expression induced by neopterin 
was even greater than that induced by LPS and seemed to be 
additive to that of LPS. The biochemical mechanisms whereby 
neopterin modulates NO production remain to be elucidated. 
Neopterin is known to enhance the effects exhibited by cyto- 
toxic reactive oxygen species originating from chloramine-T 
and hydrogen peroxide [3,4]. In a study performed at our labo- 
ratory, we found an increase in iNOS gene expression i VSMC 
following incubation with 300/~M hydrogen peroxide (unpub- 
lished observation). In addition. Adcock et al. [17] demon- 
strated a stimulation of iNOS gene expression induced by the 
superoxide anion generating compound pyrogallol, most likely 
via activation of the cellular transcription factor NF-xB. One 
may speculate that neopterin, immediately released into the 
circulation following macrophage stimulation in humans, is 
likely to play a role in amplifying macrophage-induced extracel- 
lular toxicity by potentiating the initial response to oxidative 
stress. This includes enhanced production of NO which is 
known to exhibit distinct cytotoxic effects, e.g. microbicidial 
and tumoricidial activities [18,19]. 
Another possible mechanism could be that a neopterin-in- 
duced multiplication f the effects of reactive oxygen intermedi- 
Table 1 
Nitrite levels measured incell culture supernatants following 24 h and 
48 h incubation protocol 
Nitrite tnmol/106 cells) 
24 h 48 h 
C 2.76 _+ 0.53 3.68 + 0.59 
IFN-y (100 U/ml) 22.30 _+ 1.52 ~' 82.48 + 0.85 ~ 
LPS (5/.tg/ml) 6.78_+0.39" 10.18+0.31 ~' 
Neopterin (20 ¢tM) 5.58 _+ (I.40" 12.80 + 0.26 ~ 
7,8-dihydroneopterin (20 ¢tM) 2.05 _+ 0.11 3.31 _+ 0.03 
Neopterin (20 ¢tM) + IFN-y 
(100 U/ml) 25.08 _+ 1.0(P 88.50 _+ 2.00" 
Neopterin 120 ~M) + LPS 15 ~g/ml} 1{/.13 +0.71 ~ 18.37 + 1.77 ~' 
7,8-Dihydroneopterin (20/~Mt + 
IFN-y (100 U/ml) 18.28 _+ 0.25" 48.66 +_ 1.12" 
7,8-Dihydroneopterin (20 uM) + 
LPS (5/,tg/ml) 3.15 _+ 0.46 9.75 + 0.46 ~' 
Data are expressed asmeans _+ SEM {n = 6). 
~P < 0.05 as compared to unstimulated cells {C). 
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Fig. 2. Quantitative analysis of iNOS mRNA expression detected as 
iNOS cDNA (length: 498 base pairs) following 9 h incubations of 
vascular smooth muscle cells with: 20/xM neopterin (N20), 5/tg/ml 
lipopolysaccharide (LPS), and 20/xM neopterin +5/xg/ml lipopolysac- 
charide (N20 + LPS), respectively. Lane M indicates the molecular 
marker. As described indetail in section 2, known molecular quantities 
of the standard cDNA (length: 400 base pairs) were spiked into a series 
of PCR reaction tubes containing equal concentrations of iNOS cDNA. 
Following a 25 cycled PCR the initial amount of iNOS and standard 
cDNA were assumed to be equal in those reactions where the molar 
ratio of iNOS and standard products were jugded to be equal (as 
indicated by 1). Results are representative of three different experiments. 
ates may result in programmed cell death including an increase 
in iNOS gene expression. In our study, less than 1% of the cells 
treated with neopterin or 7,8-dihydroneopterin + IFN-y and 
LPS stained with trypan blue. Furthermore, replating of cells 
following a 48 h incubation period did not result in different 
plating efficiency between VSMC exposed to the above-men- 
tioned substances and untreated cells. We conclude that, con- 
cerning our experiments, neither neopterin- nor neopterin-in- 
duced nitric oxide generation exhibited any cytotoxic effects on 
vascular smooth muscle cells. 
At present i remains peculative whether our in vitro obser- 
vations on rat VSMC are of in vivo relevance inconditions that 
are associated with increased iNOS activity in men. In this 
context, it is of special importance that human macrophages 
contain a particularly low activity of 6-pyruvoyl tetrahydrop- 
terin synthase, the second enzyme in the tetrahydrobiopterin 
(BH4) generating pathway. Its lower activity leads (a) to minor 
synthesis of BH4, an essential cofactor for iNOS activity, and 
(b) to the predominant production of 7,8-dihydroneopterin due
to the major cleaving of 7,8-dihydroneopterin t sphosphate by
phosphatases. 7,8-Dihydroneopterin is then partially oxidized 
to neopterin [2,20]. Consequently, the potential of human mac- 
rophages to produce NO is reduced. However, activation of 
human macrophages by interferon-), results in the release of 
large quantities of neopterin, thereby possibly counterbalanc- 
ing the limited macrophages dependent NO-induced cytotox- 
icity [20]. 
In our study 7,8-dihydroneopterin did not affect iNOS gene 
expression but suppressed the IFN-ig-induced augmentation f 
nitrite levels in the culture supernatants. Therefore, 7,8-dihy- 
droneopterin may act as a nitric oxide suppressor at the 
posttranscriptional level, most likely due to its recently de- 
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Fig. 3. Quantitative analysis of iNOS mRNA expression detected as 
iNOS cDNA (length: 498 base pairs) following 9 h incubations ol 
vascular smooth muscle cells with: 20/,tM neopterin (N20), 5 ~tg/ml 
lipopolysaccharide (LPS), and 20 ¢tM neopterin +5 ¢tg/ml lipopotysac- 
charide (N20 + LPS), 20 ¢tM 7,8-dihydroneopterin + lipopoly- 
saccharide (NH20 + LPS), 100 U/ml interferon-), (IFN-),), 20/IM ne- 
opterin + 100 U/ml interferon-/, (N20 + IFN-)'), and 20/IM 7,8-dihy- 
droneopterin + 100 U/ml interferon-), (NH20 + IFN-)'), respectively 
Results are representative of three different experiments. 
scribed potential to act as a scavenger of reactive oxygen species 
[3]. 
Activation of macrophages with the subsequent release of 
neopterin is a common finding in several diseases characterized 
by an activated cellular immune system [2]. Therefore, the de- 
termination of neopterin represents a usefool tool for clinical 
monitoring. It is well established that septic patients, especially 
those with fatal outcome, have increased plasma concentra- 
tions of neopterin [10]. Moreover, patients with sepsis regularly 
have high concentrations of nitrite in plasma, indicating a pro- 
nounced release of NO [21,221. It is likely that the induction of 
NO-synthase during sepsis is the final common pathway for 
vasodilatation i septic shock. Since we could demonstrate an 
iNOS gene expressing the effect of neopterin in VSMC, it is 
possible that neopterin is involved in the modulation of iNOS 
gene expression in septic patients. One might argue that the 
pronounced stimulatory effect of 1FN- T on iNOS gene expres- 
sion in VSMC could potentially superimpose any neopterin- 
induced NO release. This is not in contradiction to our concept. 
since plasma IFN-~'-levels could not be detected after E. coli 
endotoxin infusion in healthy volunteers [23] nor did they cor- 
relate with the prognosis in septic patients [24]. Our findings 
suggest that neopterin stimulates iNOS expression at the 
mRNA level. Thus, it might be involved in macrophage-in- 
duced extracellular toxicity. The in vivo relevance of neopterin 
in conditions associated with excessive nitric oxide release, e.g., 
septic shock, remains to be addressed in further clinical studies. 
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